| Peer-Reviewed

Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia

Received: 4 February 2016    Accepted: 16 February 2016    Published: 29 February 2016
Views:       Downloads:
Abstract

Measuring PCT level can be as the examination having the role to differ the systemic inflammatory response syndrome (SIRS) and sepsis. This study aims to know the PCT level in accessing the sepsis degree at pneumonia patients. This study was an analytical study with cross-sectional design. There were 30 samples obtained since February 2013 until March 2014 at the Emergency Room and Inpatient Room of Internal Medicine Local Public Hospital Dr. Zainoel Abidin Banda Aceh. The sample collection was conducted with quota sampling technique. The data was analysed with Anova and followed with LDS. The data was considered to be significant if the p value is < 0,05. The study results were obtained the minimum limit value of PCT level at pneumonia of 0,091 ng/dl, sepsis of 0,686 ng/dl, severe sepsis of 3,593 ng/dl and shock sepsis of 21,703 ng/dl. The analysis results showed that the higher PCT level makes the higher disease severity.

Published in American Journal of Internal Medicine (Volume 4, Issue 1)
DOI 10.11648/j.ajim.20160401.14
Page(s) 19-23
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Procalcitonin (PCT), Sepsis Degree, Pneumonia

References
[1] Nasronudin. Imunopatogenesis Sepsis dan Prinsip Penatalaksanaan. Penyakit Infeksi di Indones., Surabaya: Airlangga University Press; 2007, p. 238–45.
[2] Martin G, Mannino D. The epidemiology of sepsis in the United States from 1979 through 2000. New Engl J Med 2003:1546–54.
[3] Müller-Redetzky H, Suttorp N, Witzenrath M. Experimental models of pneumonia-induced sepsis. Drug Discov Today Dis Model 2012;9:e23–32. doi:10.1016/j.ddmod.2011.12.002.
[4] Engel C, Brunkhorst FM, Bone H-G, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007;33:606–18. doi:10.1007/s00134-006-0517-7.
[5] Giamarellos-bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, et al. Procalcitonin as an early indicator of outcome in sepsis : a prospective observational study 2011;77:58–63. doi:10.1016/j.jhin.2010.07.026.
[6] Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010;159:253–64. doi:10.1111/j.1476-5381.2009.00433.x.
[7] Kopterides P., Tsangaris I. Procalcitonin and sepsis : recent data on diagnostic utility, prognostic potential and therapeutic implications in critically ill patients. Minerva Anestesiol 2012:1–26.
[8] Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002;323:17–29.
[9] Ugarte H., Silva E., Mercan D., Mendonca A. D. Vincent JL. Procalcitonin used as marker of infection in the intensive care unit. Crit Care Med 1999;27:498–504.
[10] Tang BMP, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210–7. doi:10.1016/S1473-3099(07)70052-X.
[11] Azkárate I, Choperena G, Salas E, Sebastián R, Lara G, Elósegui I, et al. Epidemiology and prognostic factors in severe sepsis / septic shock. Evolution over six years. Med Intensiva (English Ed 2016;40:18–25.
[12] Sims CR, Nguyen TC, Mayeux PR. Could Biomarkers Direct Therapy for the Septic Patient ? J Pharmacol Exp Ther 2016:1–60.
[13] Signs C. Diagnosis of Pneumonia in Adults in General Practice. Scand J Prim Heal Care 1992;10:226–33.
[14] Melbye H., Straumer B., Aasebo U., Broxa J. The Diagnosis of Adult Pneumonia in General Practice. Scand J Prim Heal Care 1988;6:111–7.
[15] Hammer C, Hobel G, Hamme S, et al. Diagnosis and Monitoring of Inflammatory Events in Transplant Patients. In: Trull Ak, Demers LM, Holt DW, et. al., editor. Biomarkers Dis. An Evidence-Based Approach, Cambridge United Kingdom: Cambridge University Press; 2002, p. 474–88.
[16] Guntur H. A. SIRS, Sepsis dan Syok Septik. Surakarta: Sebelas Maret University Press; 2008.
[17] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250–6.
[18] Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Surviv Sepsis Campaign 2012.
[19] Brunkhorst F, Wegscheider K. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000;26:148–53.
[20] Harbarth S, Holeckova K, Pittet D, Ricou B, Grau GE, Vadas L. Diagnostic Value of Procalcitonin, Interleukin-6 and Interleukin-8 in Critically III Patients Admitted with Suspected Sepsis. Am J Respir Crit Care Med 2001;164:396–402.
[21] Dorizzi RM, Polati E, Sette P, Ferrari A, Rizzotti P, Luzzani A. Procalcitonin in the diagnosis of inflammation in intensive care units. Clin Biochem 2006;39:1138–43. doi:10.1016/j.clinbiochem.2006.08.011.
[22] Rau B, Krüger C, Schilling M. Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbeck’s Arch Surg 2004:134–44. doi:10.1007/s00423-004-0463-1.
[23] Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 2000;26:1193–200. doi:10.1007/s001340000624.
[24] Abu Elkhashab AE, Swelem RS, Abd Alla AED a., Hattata E a., Atta MS. Etiological and prognostic values of procalcitonin in hospital-acquired pneumonia. Egypt J Chest Dis Tuberc 2014;63:201–6. doi:10.1016/j.ejcdt.2013.09.015.
[25] BalcI C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanogu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003;3:85–90. doi:10.1186/cc1843.
[26] Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004;8:R234–42. doi:10.1186/cc2877.
[27] Jeong S, Park Y, Cho Y, Kim H-S. Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture. Clin Chim Acta 2012;413:1731–6. doi:10.1016/j.cca.2012.06.030.
[28] Köszegi T. Immunoluminometric detection of human procalcitonin. J Biochem Biophys Methods 2002;53:157–64.
[29] Sibila O, Meduri GU, Mortensen EM, Anzueto A, Laserna E, Fernandez JF, et al. Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission. J Crit Care 2013;28:284–90.
Cite This Article
  • APA Style

    Agus Prima, Wachyoe Hadi Saputra. (2016). Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia. American Journal of Internal Medicine, 4(1), 19-23. https://doi.org/10.11648/j.ajim.20160401.14

    Copy | Download

    ACS Style

    Agus Prima; Wachyoe Hadi Saputra. Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia. Am. J. Intern. Med. 2016, 4(1), 19-23. doi: 10.11648/j.ajim.20160401.14

    Copy | Download

    AMA Style

    Agus Prima, Wachyoe Hadi Saputra. Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia. Am J Intern Med. 2016;4(1):19-23. doi: 10.11648/j.ajim.20160401.14

    Copy | Download

  • @article{10.11648/j.ajim.20160401.14,
      author = {Agus Prima and Wachyoe Hadi Saputra},
      title = {Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia},
      journal = {American Journal of Internal Medicine},
      volume = {4},
      number = {1},
      pages = {19-23},
      doi = {10.11648/j.ajim.20160401.14},
      url = {https://doi.org/10.11648/j.ajim.20160401.14},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20160401.14},
      abstract = {Measuring PCT level can be as the examination having the role to differ the systemic inflammatory response syndrome (SIRS) and sepsis. This study aims to know the PCT level in accessing the sepsis degree at pneumonia patients. This study was an analytical study with cross-sectional design. There were 30 samples obtained since February 2013 until March 2014 at the Emergency Room and Inpatient Room of Internal Medicine Local Public Hospital Dr. Zainoel Abidin Banda Aceh. The sample collection was conducted with quota sampling technique. The data was analysed with Anova and followed with LDS. The data was considered to be significant if the p value is < 0,05. The study results were obtained the minimum limit value of PCT level at pneumonia of 0,091 ng/dl, sepsis of 0,686 ng/dl, severe sepsis of 3,593 ng/dl and shock sepsis of 21,703 ng/dl. The analysis results showed that the higher PCT level makes the higher disease severity.},
     year = {2016}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia
    AU  - Agus Prima
    AU  - Wachyoe Hadi Saputra
    Y1  - 2016/02/29
    PY  - 2016
    N1  - https://doi.org/10.11648/j.ajim.20160401.14
    DO  - 10.11648/j.ajim.20160401.14
    T2  - American Journal of Internal Medicine
    JF  - American Journal of Internal Medicine
    JO  - American Journal of Internal Medicine
    SP  - 19
    EP  - 23
    PB  - Science Publishing Group
    SN  - 2330-4324
    UR  - https://doi.org/10.11648/j.ajim.20160401.14
    AB  - Measuring PCT level can be as the examination having the role to differ the systemic inflammatory response syndrome (SIRS) and sepsis. This study aims to know the PCT level in accessing the sepsis degree at pneumonia patients. This study was an analytical study with cross-sectional design. There were 30 samples obtained since February 2013 until March 2014 at the Emergency Room and Inpatient Room of Internal Medicine Local Public Hospital Dr. Zainoel Abidin Banda Aceh. The sample collection was conducted with quota sampling technique. The data was analysed with Anova and followed with LDS. The data was considered to be significant if the p value is < 0,05. The study results were obtained the minimum limit value of PCT level at pneumonia of 0,091 ng/dl, sepsis of 0,686 ng/dl, severe sepsis of 3,593 ng/dl and shock sepsis of 21,703 ng/dl. The analysis results showed that the higher PCT level makes the higher disease severity.
    VL  - 4
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Department of Internal Medicine, Ibnu Sina Hospital, Aceh, Indonesia

  • Department of Internal Medicine, Mother and Child Hospital, Aceh, Indonesia

  • Sections